UNISOUND (ASX: 09678) has announced significant progress following the official launch of its next-generation U2 foundational model. The company reports a substantial leap in the comprehensive capabilities of its underlying general-purpose large model, which has markedly accelerated the iteration efficiency of vertical industry models.

Recently, leveraging its extensive data assets accumulated in the healthcare sector and a deep understanding of various medical business scenarios, the company unveiled "U2-Med," the industry's first specialized large model for healthcare, medical insurance (including commercial insurance), and pharmaceuticals. This move further solidifies the company's leading position in large model capabilities within the broader healthcare field.

Capitalizing on these competitive advantages, the company has recently secured a series of artificial intelligence medical construction projects from several top-tier domestic hospitals. These projects involve leading regional medical institutions such as the Beijing You'an Hospital affiliated with Capital Medical University, Shandong Provincial Hospital affiliated with Shandong First Medical University, and Nanjing Tongren Hospital. The successful implementation of these landmark projects not only reinforces the company's core competitive edge in the high-end market but also signifies that its medical large model has entered a new phase of large-scale commercial replication.

The series of confirmed orders fully demonstrates that the company's medical large model has established a mature, standardized, and rapidly scalable delivery system. This system can be quickly adapted to meet the intelligent construction needs of different hospital departments and types, setting a benchmark example for the commercial deployment of medical large models in China.

Looking ahead, the company will continue to deepen the application and innovation of large models in the broader healthcare sector. It aims to leverage its self-developed AI core technology foundation to unlock high-token industrial value and promote the evolution of medical large models into industrial infrastructure. Concurrently, the company will further enhance its standardized and scalable delivery capabilities to assist medical institutions in improving quality and efficiency, thereby consolidating its leadership in the commercialization of medical large models.